Valuation: PTC Therapeutics, Inc.

Market Cap 6.13B 5.26B 4.94B 4.51B 8.51B 585B 8.56B 58.46B 22.66B 295B 23.02B 22.52B 977B P/E 2026 *
48.1x
P/E 2027 * 27.2x
Enterprise Value 4.26B 3.66B 3.43B 3.13B 5.92B 406B 5.95B 40.62B 15.74B 205B 16B 15.65B 679B EV / Sales 2026 *
3.39x
EV / Sales 2027 * 2.91x
Free-Float
92.69%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: PTC Therapeutics, Inc.

1 day-0.30%
1 week-0.75%
Current month+7.51%
1 month-3.54%
3 months+8.08%
6 months+7.36%
Current year-3.75%
1 week 68.02
Extreme 68.02
73.56
1 month 64.57
Extreme 64.5675
79.33
Current year 61.43
Extreme 61.43
90.87
1 year 48.86
Extreme 48.86
90.87
3 years 17.53
Extreme 17.53
90.87
5 years 17.53
Extreme 17.53
90.87
10 years 4.03
Extreme 4.03
90.87
Manager TitleAgeSince
Chief Executive Officer 54 22/03/2023
Director of Finance/CFO 41 13/07/2023
Chief Tech/Sci/R&D Officer - 01/10/2017
Director TitleAgeSince
Chairman 74 01/11/2004
Chairman 80 31/03/1998
Director/Board Member 65 01/12/2005
Date Insider Type Main position Quantity % Market Cap.
20/8/26
Section Six Partners
SellCompany -12,500 0.0151%
19/8/26 Other

Chairman

0 0%
17/8/26 Fiscal year

General Counsel

8,439 0.0102%
Change 5-day change 1-year change 3-year change Capi.($)
-0.30%-0.75%+47.83%+82.70% 6.13B
-3.41%-7.13%+61.55%+114.66% 1,100B
-0.97%-1.03%+53.32%+64.71% 658B
-1.75%-1.70%+25.48%+77.34% 470B
-1.47%+0.24%+42.09%+42.12% 372B
-0.90%+0.05%+25.57%+40.59% 304B
-1.94%+1.53%+3.05%+13.24% 264B
-0.18%-0.23%+52.41%+72.03% 239B
-0.93%+1.84%-13.11%-52.83% 213B
-0.20%+0.70%+29.53%+92.93% 184B
Average -1.13%+2.82%+32.77%+54.75% 380.9B
Weighted average by Cap. -1.71%+2.21%+40.55%+68.29%

Financials

2026 *2027 *
Net sales 1.26B 1.08B 1.01B 924M 1.74B 120B 1.75B 11.97B 4.64B 60.41B 4.71B 4.61B 200B 1.37B 1.18B 1.1B 1.01B 1.9B 131B 1.91B 13.06B 5.06B 65.9B 5.14B 5.03B 218B
Net income 144M 124M 116M 106M 200M 13.76B 201M 1.38B 533M 6.94B 542M 530M 22.99B 216M 186M 174M 159M 301M 20.64B 302M 2.06B 800M 10.41B 813M 795M 34.49B
Net Debt -1.87B -1.61B -1.51B -1.38B -2.6B -178B -2.61B -17.84B -6.91B -90.03B -7.03B -6.87B -298B -2.15B -1.84B -1.73B -1.58B -2.98B -205B -2.99B -20.45B -7.93B -103B -8.06B -7.88B -342B
Logo PTC Therapeutics, Inc.
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Employees
991
Date Price Change Volume
27/08/26 USD 73.08 -0.54% 151,584
25/08/26 USD 73.47 +3.39% 624,463
24/08/26 USD 71.06 +1.78% 897,681
21/08/26 USD 69.82 -0.99% 674,738
20/08/26 USD 70.52 -4.28% 802,507
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
73.47USD
Average target price
99.29USD
Spread / Average Target
+35.14%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTCT Stock